...
首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
【24h】

Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.

机译:替米沙坦对一氧化氮-不对称二甲基精氨酸系统的影响:内皮细胞衰老过程中血管紧张素II 1型受体γ和过氧化物酶体增殖物激活受体gamma信号的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Telmisartan, in addition to blocking angiotensin (Ang) II type 1 receptor (AT(1)R), activates peroxisome proliferator activated receptor gamma (PPARgamma) signaling that interferes with nitric oxide (NO) system. Because aging of endothelial cells (ECs) is hallmarked by a reduction in NO synthesis, we hypothesized that telmisartan increases NO formation by regulated asymmetrical dimethylarginine (ADMA)-dimethylarginine dimethylaminohydrolase (DDAH)-system through blocking AT(1)R and activating PPARgamma signaling. To test this hypothesis, ECs were cultured with telmisartan, eprosartan, Ang II, and GW9662 (PPARgamma antagonist) until the twelfth passage. During the process of aging, PPARgamma protein expression decreased significantly, whereas the expression of AT(1)R increased. Telmisartan reversed these effects and dose-dependently decreased reactive oxygen species and 8-iso-prostaglandin (PG) F(2alpha) formation. This effect was associated with an upregulated activity and protein expression of DDAH, accompanied by a decrease in ADMA concentration, an increase in NO metabolites, and delayed senescence. Blockade of PPARgamma signaling by GW9662 or PPARgamma small-interference RNA prevented the effect of telmisartan on ADMA-DDAH-NO system. Coincubation with Ang II did not affect the effect of telmisartan-delayed senescence, whereas Ang II itself accelerated endothelial aging. Moreover, AT(1)R blocker eprosartan that did not influence PPARgamma protein expression had no effect on ADMA system and senescence. We have demonstrated that telmisartan mainly by activating PPARgamma signaling can alter the catabolism and release of ADMA as an important cardiovascular risk factor. We therefore propose that telmisartan translationally and posttranslationally upregulated DDAH expression via activation of PPARgamma signaling, causing ADMA to diminish and increase NO synthesis sufficient to delay senescence.
机译:替米沙坦除了能阻断1型血管紧张素(Ang)II受体(AT(1)R)外,还可以激活过氧化物酶体增殖物激活受体γ(PPARgamma)信号,从而干扰一氧化氮(NO)系统。因为内皮细胞(ECs)的老化是NO合成减少的标志,所以我们假设替米沙坦通过阻断AT(1)R和激活PPARgamma信号传导,通过调节不对称二甲基精氨酸(ADMA)-二甲基精氨酸二甲基氨基水解酶(DDAH)系统增加了NO的形成。 。为了检验该假设,将EC与替米沙坦,依普罗沙坦,Ang II和GW9662(PPARγ拮抗剂)一起培养直至第十二代。在衰老过程中,PPARgamma蛋白表达显着下降,而AT(1)R的表达则增加。替米沙坦逆转了这些作用,并剂量依赖性地减少了活性氧和8-异前列腺素(PG)F(2alpha)的形成。这种作用与DDAH的活性和蛋白质表达上调有关,伴随着ADMA浓度的降低,NO代谢物的增加和衰老的延迟。 GW9662或PPARgamma小干扰RNA对PPARgamma信号的阻断阻止了替米沙坦对ADMA-DDAH-NO系统的影响。与Ang II共同孵育不会影响替米沙坦延缓衰老的作用,而Ang II本身会加速内皮细胞的衰老。此外,不影响PPARgamma蛋白表达的AT(1)R阻断剂依普罗沙坦对ADMA系统和衰老没有影响。我们已经证明,替米沙坦主要通过激活PPARgamma信号传导,可以改变ADMA的分解代谢和释放,将其作为重要的心血管危险因素。因此,我们建议替米沙坦通过激活PPARgamma信号来翻译和翻译后上调DDAH表达,从而使ADMA减少并增加NO合成,足以延迟衰老。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号